Ansuvimab (Ansuvimab-zyk; mAb114) is a humanizing neutralizing monoclonal antibody targeting the glycoprotein (GP) of Zaire ebolavirus (EBOV). The antibody specifically binds to a highly conserved epitope (LEIKKPDGS) within the receptor-binding site of the EBOV GP1 subunit, effectively blocking the interaction between the viral glycoprotein and the host intracellular Niemann-Pick C1 (NPC1) receptor. In addition to its neutralizing activity, Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) to facilitate the clearance of infected cells by the immune system. As the first approved treatment for Ebola virus infection, it possesses significant clinical value in reducing viral load and improving patient survival rates.